Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Transactions
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
BeiGene, Ltd. (BGNE) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/02/2023 8-K Quarterly results
07/24/2023 8-K Quarterly results
07/11/2023 8-K Termination of a Material Definitive Agreement, Other Events, Financial Statements and Exhibits  Interactive ...
05/26/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "BeiGene Presentations at the 2023 ASCO Annual Meeting Reinforce Promise Across Oncology Portfolio Highlights from early- and late-stage pipeline include"
05/08/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "BeiGene Receives New Approvals for BRUKINSA® in China BRUKINSA is approved for first-line treatment for CLL/SLL and WM in China and has multiple approved indications in more than 65 markets worldwide"
05/04/2023 8-K Quarterly results
04/25/2023 8-K Quarterly results
04/20/2023 8-K Quarterly results
03/29/2023 8-K Quarterly results
02/27/2023 8-K Quarterly results
Docs: "BeiGene Reports Fourth Quarter and Full Year 2022 Financial Results",
"BeiGene Receives 10th Approval for PD-1 Inhibitor Tislelizumab in China NMPA grants approval for first-line use in combination with chemotherapy in advanced gastric or gastroesophageal junction adenocarcinoma with high PD-L1 expression"
01/31/2023 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
01/23/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "BeiGene Announces Expansion of Coverage on China’s National Reimbursement Drug List Four new indications added for tislelizumab and all nine approved indications now included in NRDL KYPROLIS® included for the first time XGEVA® successfully renewed",
"BRUKINSA® Approved in the U.S. for Chronic Lymphocytic Leukemia Two global Phase 3 trials in adult CLL patients demonstrated superior efficacy for BRUKINSA in first-line and relapsed/refractory treatment settings"
01/05/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "BeiGene Announces Acceptance of 12th Regulatory Submission in China for PD-1 Inhibitor Tislelizumab Submission seeks marketing authorization for first-line treatment of unresectable or metastatic hepatocellular carcinoma"
12/19/2022 8-K Quarterly results
11/22/2022 8-K Quarterly results
11/09/2022 8-K Quarterly results
11/07/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "BeiGene Receives European Commission Approval for BRUKINSA® for the Treatment of Adults with Marginal Zone Lymphoma BRUKINSA is the first and only Bruton’s Tyrosine Kinase inhibitor for marginal zone lymphoma approved in the European Union"
10/14/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "BeiGene Announces Positive Topline Results from Final Progression-Free Survival Analysis of BRUKINSA® Compared to IMBRUVICA® in Phase 3 Chronic Lymphocytic Leukemia Trial",
"BeiGene Receives Positive CHMP Opinion for BRUKINSA® for the Treatment of Adults With CLL If approved, BRUKINSA would be the only BTK inhibitor for CLL in the European Union to achieve superior efficacy versus standard of care in head-to-head trials"
09/22/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "BeiGene Receives Positive CHMP Opinion for BRUKINSA® for the Treatment of Adults with Marginal Zone Lymphoma CHMP recommends approval of BRUKINSA for the treatment of relapsed or refractory marginal zone lymphoma",
"NICE Recommends BeiGene’s BRUKINSA® for Patients with Waldenström’s Macroglobulinemia who have had at Least One Treatment BRUKINSA Is the First Bruton’s Tyrosine Kinase Inhibitor Recommended by NICE for Routine Use for WM"
09/15/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "BeiGene Announces Data Presentations at ESMO 2022 Including Late-Breaking Oral Presentation for Tislelizumab in First-Line Unresectable Hepatocellular Cancer Tislelizumab demonstrated non-inferiority for overall survival and favorable safety profile versus sorafenib in global Phase 3 trial"
08/30/2022 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "Financial Information"
08/25/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "BeiGene Announces Acceptance of 11th Regulatory Submission for PD-1 Inhibitor Tislelizumab in China Submission seeks marketing authorization for first-line use in combination with chemotherapy in advanced esophageal squamous cell carcinoma"
08/10/2022 8-K Quarterly results
08/04/2022 8-K Quarterly results
Docs: "BeiGene Reports Second Quarter 2022 Financial Results"
07/20/2022 8-K Quarterly results
07/15/2022 8-K Quarterly results
06/30/2022 8-K Quarterly results
06/22/2022 8-K Quarterly results
06/14/2022 8-K Quarterly results
05/27/2022 8-K Quarterly results
05/05/2022 8-K Quarterly results
04/28/2022 8-K Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Financial Information",
"Global Phase 3 Trial of BeiGene’s PD-1 Inhibitor, Tislelizumab, in Combination with Chemotherapy Meets Primary Endpoint in First-Line Advanced Esophageal Squamous Cell Carcinoma •Statistically significant and clinically meaningful improvement in overall survival achieved for tislelizumab and chemotherapy compared to placebo and chemotherapy"
04/20/2022 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "China NMPA Approves Tislelizumab for Patients with Second-Line Esophageal Squamous Cell Carcinoma Tislelizumab is now approved for eight indications in China",
"BeiGene Presents Updated Results from Phase 3 RATIONALE-309 Trial of PD-1 Inhibitor Tislelizumab in First-Line RM-NPC in Virtual ASCO Plenary Series Progression-Free Survival Benefit of Tislelizumab in Combination with Chemotherapy Sustained at Median 15.5 Month Follow-up"
04/12/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "BeiGene Announces European Medicines Agency Acceptance of Marketing Authorization Applications for Tislelizumab for the Treatment of Patients with ESCC and NSCLC First European Submissions for BeiGene’s Anti PD-1 antibody Licensed to Novartis for North America, Europe and Japan",
"IRC Determines BRUKINSA® Demonstrates Superior Overall Response Rate Versus Ibrutinib in Final Response Analysis of ALPINE Trial in Chronic Lymphocytic Leukemia Final Response Analysis from Global Phase 3 ALPINE Trial Provides Additional Support for Potential Use of BRUKINSA in Relapsed or Refractory CLL/SLL"
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy